Hologic wraps up Biotheranostics acquisition

By LabPulse.com staff writers

February 22, 2021 -- Hologic has completed the acquisition of cancer test developer Biotheranostics. Hologic is gaining access to two laboratory-developed tests as part of the deal.

Hologic had unveiled plans to acquire Biotheranostics for $230 million in January. Through the deal, Hologic gains two laboratory-developed tests -- the Breast Cancer Index, which predicts effects of endocrine therapy in breast cancer patients and CancerType ID, which aids in the molecular characterization of uncertain and unknown cancers.

Hologic inks deal with Google to unite cloud with diagnostics
Hologic has announced a collaboration with Google designed to advance the potential of digital diagnostics for cervical cancer screening by making Google...
Diagnostics growth drives Hologic's Q1 results higher
Strong growth in its molecular diagnostics business -- with revenues almost tripling due to the COVID-19 pandemic -- helped drive first-quarter preliminary...
Hologic buys Biotheranostics molecular testing firm
Hologic continues to start 2021 with a bang. The company announced on January 5 that it is acquiring Biotheranostics, a developer of molecular tests for...
Hologic scores $119M COVID-19 testing contract
The U.S. government has awarded a $119 million contract to Hologic to expand its production capacity for COVID-19 molecular tests.

Copyright © 2021 LabPulse.com

Last Updated ls 2/22/2021 4:00:59 PM